His group basic science research aims to dissect the pathogenesis mechanism of autoimmune liver diseases, immune mediated and drug induced/check point inhibitors liver injury with TransOMICS approach, deep immune profiling and develop personalised and stratified therapies. His team develop and deliver translational GMP Regulatory T clinical trials in autoimmune liver diseases.